HIMS Stock Forecast & Price Target

Hims & Hers Health is experiencing significant growth, with total membership on personalized products increasing by 55% year-over-year, suggesting a robust demand for its diverse telehealth offerings. The company is projected to expand its international revenue to nearly $1 billion by FY30, representing a nearly tenfold increase from its implied FY25 run rate, driven by new treatments, market expansion, and enhancements in user experience. Additionally, core U.S. revenue is expected to grow approximately 21% annually, fueled predominantly by subscriber growth and higher revenue per subscriber through personalization and cross-selling strategies.

Hims & Hers Health has experienced a significant downturn, with its stock price dropping over 20% since late July despite a year-to-date increase exceeding 100%, primarily due to concerns regarding slowing core growth. Fundamental challenges such as slower adoption of personalized treatments, regulatory risks within the healthcare industry, and potential difficulties in sustaining revenue growth amid increasing competition are contributing to a negative outlook for the company. Additionally, Hims' reliance on consumer spending for its direct-to-consumer subscriptions raises concerns about its financial stability in the face of a declining macroeconomic environment.